## TMO: Thermo Fisher Scientific Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 3.7% below STRENGTH zone (4.0-10.0%); PEG 2.14 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($572.13)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Inside the Thermo Fisher Microscope Revolution: Why These Labs-Grade Eyes Are Suddenly Everywhere**
- Source: AD HOC NEWS | 20260101T110842 | Bullish | Relevance: 100%
- Thermo Fisher microscopes are increasingly becoming the standard in advanced imaging labs due to their superior image quality, stability, and integration. While expensive, their automation, high resolution, and robust support system make them invaluable for research demanding reproducible and high-confidence data. These instruments are designed as critical infrastructure, catering to complex scientific workflows rather than simple inspection tasks.

**2. Generate Investment Management Ltd Invests $7.47 Million in Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20251231T113616 | Somewhat-Bullish | Relevance: 100%
- Generate Investment Management Ltd reported acquiring a new stake of 15,403 shares in Thermo Fisher Scientific Inc., valued at approximately $7.47 million during the third quarter. Institutional ownership of TMO now stands at about 89.23%, despite recent net selling by company insiders. Thermo Fisher Scientific has outperformed Q3 expectations and analysts have a "Moderate Buy" consensus rating with an average target price of $616.60.

**3. Thermo Fisher Scientific Inc. $TMO Shares Purchased by Allspring Global Investments Holdings LLC**
- Source: MarketBeat | 20260102T082532 | Bullish | Relevance: 100%
- Allspring Global Investments Holdings LLC increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.6% during the third quarter, holding 117,281 shares valued at $62.245 million. This move is part of broader institutional interest, with other major funds also adjusting their positions in the medical research company. Insiders, however, have recently sold a significant number of shares, totaling over $86 million in the last ninety days.

**4. Bank Pictet & Cie Europe AG Sells 3,510 Shares of Thermo Fisher Scientific Inc. $TMO**
- Source: MarketBeat | 20260102T080838 | Somewhat-Bullish | Relevance: 100%
- Bank Pictet & Cie Europe AG has reduced its stake in Thermo Fisher Scientific Inc. by selling 3,510 shares, now holding 36,194 shares valued at $17.56 million. Other institutional investors have also adjusted their holdings, while insiders have sold a significant number of shares recently. Thermo Fisher Scientific reported strong quarterly earnings, beating estimates, and announced a new stock buyback program for $5.00 billion along with a quarterly dividend of $0.43.

**5. What to expect from Thermo Fisher Scientific's next quarterly earnings report**
- Source: MSN | 20260102T040857 | Neutral | Relevance: 100%
- The article is a placeholder with "MSN" as its only content, indicating that detailed information about Thermo Fisher Scientific's next quarterly earnings report is expected but not yet available. It sets an expectation for upcoming financial news without providing any specifics.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Wells Fargo | $675 | $635 | +6% |
| 2025-12-11 | Citigroup | $660 | $580 | +14% |
| 2025-12-09 | Goldman Sachs | $685 | $0 | 0% |
| 2025-12-08 | Keybanc | $750 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Wells Fargo | main | Overweight |
| 2025-12-11 | Citigroup | up | Buy |
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-08 | Keybanc | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 4 ($8.01M) |
| Sells | 12 ($5.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.0% (+0.2%)
- Blackrock Inc.: 7.9% (+8.4%)
- State Street Corpora: 4.4% (-0.6%)
- JPMORGAN CHASE & CO: 3.9% (+58.9%)
- Morgan Stanley: 3.4% (-1.2%)

### Key Risks

1. Insider selling cluster: $5.3M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_20 improving +3.5% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.14 elevated, pricing in significant growth expectations. Forward P/E 24.0x stretched relative to 8% growth. Balance sheet: $1.8B free cash flow. Analyst sentiment positive (2 raises, avg +10%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $222.6B |
| Beta | 0.90 |
| 52W Range | $385.46 - $610.97 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.14 |
| Forward P/E | 24.0 |
| Current P/E | 26.1 |
| YoY Growth | 8.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from 0.1% to 3.7% (+3.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.3pp (needs >4.0% for momentum thesis). MRS_5 at 2.1% confirms short-term momentum alignment. AM_20 at 3.1% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.31), confirming momentum. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.67% (CS: 84) | Neutral |
| RSI_14 | 62.4 | Neutral |
| MACD Histogram | 1.31 | Bullish |
| vs SMA20 | 1.031x | Above |
| vs SMA50 | 1.030x | Above |
| vs SMA200 | 1.220x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $592.51
- **Stop Loss:** $572.13 (3.4% risk)
- **Target:** $612.89 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 70
- **Position Value:** $41,475.70
- **Portfolio %:** 41.48%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-01-29 (Est: $6.45)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.50 | $5.79 | +5.3% |
| 2025Q2 | $5.23 | $5.36 | +2.5% |
| 2025Q1 | $5.10 | $5.15 | +0.9% |
| 2024Q4 | $5.94 | $6.10 | +2.7% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*